Asma Aboelezz and Dr. Sherif Mahmoud article published in Journal of the American Pharmacists Association
Congratulations to Asma Aboelezz & Dr. Sherif Mahmoud for the publication of their recent paper in the Journal of the American Pharmacists Association.
Title: Acyclovir dosing in herpes encephalitis: A scoping review
Authors: Asma Aboelezz, Sherif Hanafy Mahmoud
Abstract: Background: Herpes encephalitis, a rare yet potentially fatal viral infection, is treated exclusively with acyclovir, the sole antiviral medication used for this condition. Acyclovir recommended dose is 10 mg/kg/dose intravenous every 8 hours; however, it is unclear what body weight should be utilized in obese patients. Using the ideal body weight may result in subtherapeutic ineffective concentrations, while utilizing the actual body weight might result in acyclovir induced adverse effects, either nephrotoxicity or neurotoxicity or both.
Objective: The objective of this scoping review is to explore existing evidence regarding
acyclovir dosing for obese patients afflicted with herpes encephalitis.
Methods: MEDLINE, EMBASE, Scopus, Web of Science, and CINAHL databases were searched on 26 May 2023, with no language restrictions. Two independent reviewers utilized the Covidence software to carry out the screening and selection of the articles. A total of 22 articles were included in the current review.
Results: The prevalence of acyclovir-associated nephrotoxicity ranged from 13% to 21%, while the prevalence of neurotoxicity was not clearly defined. However, there is lack of evidence regarding what may arise from subtherapeutic concentrations. An approach has been suggested to help clinicians to give the most appropriate acyclovir dose to herpes encephalitis patients. Patients with normal kidney function could receive the normal doses based on actual weight if normal weight and based on adjusted body weight if obese. On the other hand, if the patients are experiencing augmented renal clearance, they could receive up to the maximum recommended doses.
Conclusion: Overall, there is a lack of consistency on which body weight to use to calculate
acyclovir dose in obese patients. So it is recommended that further studies compare the
concentration of intravenous acyclovir between obese and nonobese patients and relating the resultant concentration with patient outcomes.
Comments